GlassScriptPhysician profile
Joelle P Hamilton
NPI 1578574851
$360,962.29
in general payments reported to CMS, 2019-2025
39 companies · $18K in 2025
The $18K reported for 2025 was more than what 86% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $60K · 2021: $51K · 2022: $61K · 2023: $92K · 2024: $53K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Consulting Fee: $23K · Travel and Lodging: $20K · Food and Beverage: $6,111 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $113,717.00 |
| Consulting Fee | $23,264.45 |
| Travel and Lodging | $19,512.35 |
| Food and Beverage | $6,110.74 |
| Education | $236.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $198,932.13 | 2019-2025 | |
| Janssen Biotech, INC. | $116,747.44 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Pfizer INC. | $24,960.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $4,496.73 | 2019-2024 | Lynparza |
| Clovis Oncology, INC. | $3,700.00 | 2020 | |
| Genzyme Corporation | $3,034.74 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $1,824.00 | 2024 | Adstiladrin |
| Janssen Scientific Affairs, LLC | $1,507.50 | 2019-2022 | |
| Astellas Pharma US INC | $1,235.95 | 2019-2024 | Xtandi, Padcev |
| Merck Sharp & Dohme LLC | $836.14 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Dendreon Pharmaceuticals LLC | $640.09 | 2019-2024 | Provenge |
| E.R. Squibb & Sons, L.L.C. | $353.02 | 2019-2024 | Opdivo |
| Eisai INC. | $347.06 | 2019-2024 | |
| Amgen INC. | $311.39 | 2019-2021 | |
| Tempus Ai, INC | $276.25 | 2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $261.01 | 2019-2024 | Yonsa |
| Novartis Pharmaceuticals Corporation | $215.03 | 2019-2024 | |
| Progenics Pharmaceuticals, INC. | $185.48 | 2023-2024 | Pylarify |
| Blue Earth Diagnostics | $127.15 | 2019-2023 | |
| Myriad Genetic Laboratories, INC. | $112.10 | 2020-2024 | Myrisk, Prolaris |
| Exelixis INC. | $105.14 | 2019-2023 | Cabometyx |
| Sumitomo Pharma America, INC. | $97.10 | 2023-2024 | Orgovyx |
| Seagen INC. | $96.39 | 2022-2023 | Padcev |
| Gilead Sciences, INC. | $89.18 | 2022-2024 | |
| Telix Pharmaceuticals | $79.62 | 2023-2024 | Illuccix |
| Aveo Pharmaceuticals, INC. | $78.01 | 2022-2023 | Fotivda |
| Abbvie INC. | $52.51 | 2022-2023 | |
| Emd Serono, INC. | $46.68 | 2020-2023 | Bavencio |
| Myovant Sciences INC. | $43.60 | 2021-2022 | |
| Medtronic, INC. | $33.65 | 2021 | |
| Alexion Pharmaceuticals, INC. | $22.26 | 2019 | |
| Mylan Institutional INC. | $19.08 | 2019 | |
| Coherus Oncology, INC. | $17.70 | 2022 | |
| Foundation Medicine, INC. | $16.96 | 2023 | |
| Tolmar, INC. | $16.34 | 2023 | |
| Caris Mpi, INC. | $15.88 | 2025 | Mi Cancer Seek |
| Helsinn Therapeutics (U.S.), INC. | $14.96 | 2019 | |
| Axonics, INC. | $13.76 | 2023 | Axonics |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joelle Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.